Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis.

Ngamcherdtrakul W, Sangvanich T, Goodyear S, Reda M, Gu S, Castro DJ, Punnakitikashem P, Yantasee W.

Bioengineering (Basel). 2019 Mar 15;6(1). pii: E23. doi: 10.3390/bioengineering6010023.

2.

Removal of a gadolinium based contrast agent by a novel sorbent hemoperfusion in a chronic kidney disease (CKD) rodent model.

Ngamcherdtrakul W, Morry J, Sangvanich T, Reda M, Bejan DS, Fryxell GE, Yantasee W.

Sci Rep. 2019 Jan 24;9(1):709. doi: 10.1038/s41598-018-37348-2.

3.

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery.

Ngamcherdtrakul W, Sangvanich T, Reda M, Gu S, Bejan D, Yantasee W.

Int J Nanomedicine. 2018 Jul 10;13:4015-4027. doi: 10.2147/IJN.S164393. eCollection 2018.

4.

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W.

PLoS One. 2018 Jun 7;13(6):e0198141. doi: 10.1371/journal.pone.0198141. eCollection 2018.

5.

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.

Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T, Gray JW, Yantasee W.

Mol Cancer Ther. 2017 Apr;16(4):763-772. doi: 10.1158/1535-7163.MCT-16-0644. Epub 2017 Jan 30.

6.

Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

Ngamcherdtrakul W, Castro DJ, Gu S, Morry J, Reda M, Gray JW, Yantasee W.

Cancer Treat Rev. 2016 Apr;45:19-29. doi: 10.1016/j.ctrv.2016.02.005. Epub 2016 Feb 22. Review.

7.

Therapeutic siRNA for drug-resistant HER2-positive breast cancer.

Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W.

Oncotarget. 2016 Mar 22;7(12):14727-41. doi: 10.18632/oncotarget.7409.

8.

Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.

Morry J, Ngamcherdtrakul W, Gu S, Goodyear SM, Castro DJ, Reda MM, Sangvanich T, Yantasee W.

Biomaterials. 2015 Oct;66:41-52. doi: 10.1016/j.biomaterials.2015.07.005. Epub 2015 Jul 10. Erratum in: Biomaterials. 2016 Jan;74:292.

9.

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.

Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, Reda MM, Lee R, Mihelic SA, Beckman BL, Hu Z, Gray JW, Yantasee W.

Adv Funct Mater. 2015 May 13;25(18):2646-2659.

Supplemental Content

Loading ...
Support Center